Skip to main content

MDRNA Licenses Technology From RiboTask

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDRNA today said it has acquired the exclusive rights to develop, make, use, and sell unlocked nucleobase analog-based diagnostics from RiboTask.

The agreement expands a previous agreement between the two firms for exclusive rights to develop UsiRNA-based therapeutics. As a result of today's announcement and previously obtained exclusive rights to conformationally restricted nucleotide technology for both therapeutics and diagnostics, MDRNA now has one of the few intellectual property portfolios that support a nucleic acid-based personalized medicine platform and the ability to pursue proprietary nucleic acid-based therapeutics and diagnostics, the Bothell, Wash., firm said in a statement.

Ribotask, a privately owned Danish firm, which develops and synthesizes RNA chemistries, keeps co-exclusive right to manufacture, sell, and sublicense UNA technology for reagents development.

Financial terms of the deal were not disclosed.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.